-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Underweight on Celldex Therapeutics, Lowers Price Target to $21

Benzinga·11/11/2025 15:03:57
Listen to the news
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and lowers the price target from $25 to $21.